Bextra Indications

Bextra, removed from the market at the request of the FDA, carries indications for relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis and for the treatment of primary dysmenorrhea.

Rheumatoid Arthritis Indications

Rheumatoid arthritis is described as a chronic condition involving joint inflammation and degeneration. Symptoms include soreness in the joints, particularly the hands, feet, wrists, elbows and ankles.

Rheumatoid arthritis treatments include rest and diet, exercise, physiotherapy, anti-inflammatory drugs and other therapies. Some cases require surgery.

Osteoarthritis Indications

Osteoarthritis is defined as a degenerative joint disease and is the most common type of arthritis. Symptoms include stiffness of the joints in the morning, trouble with a few joints and tenderness.

Osteoarthritis treatments include rehabilitation, exercise, education for coping, acetaminophen and other painkilling drugs.

Dysmenorrhea Indications

Dysmenorrhea is described as pain with ovulation when lesions are not present. Any discomfort may be the result of abnormally induced uterine contractions. Symptoms include lower abdominal pain, aches in the lower back or legs, expelling of clots or similar matter, headache, nausea, constipation, diarrhea, urinary tract infection and typically premenstrual syndrome symptoms.

Primary dysmenorrhea treatments include ibuprofen and similar painkillers, low-dose estrogen supplements, rest and exercise.

The FDA recall of Bextra make these indications a moot point. Anyone taking Bextra for these indications and who have suffered serious side effects, should consult a Bextra attorney immediately.